Innovation for Health - 13 February 2020
Contact I4H Bootcamp Global Investor Forum
LinkedIn
Twitter
Facebook
Innovation for Health - Shaping the future of healthcare

Paul Vulto

Managing Director & Co-Founder, Mimetas
Paul Vulto

Session

14:45 - 16:00
Impact of innovation on regulatory sciences

Paul Vulto is CEO and co-founder of MIMETAS. Under his guidance, MIMETAS developed into a multinational company with operations in Europe, US and Japan. MIMETAS currently works with the majority of top-50 pharma companies and counts over 85 co-workers. Paul is the inventor behind the OrganoPlate® platform and PhaseGuide technology of MIMETAS. Prior to founding MIMETAS, Paul worked for the high-tech company Silicon Biosystems in Bologna, the Institute for Microsystems Engineering (IMTEK) at the University of Freiburg and the Leiden Academic Centre for Drug Research, Leiden University. Paul holds a cum Laude masters degree in Electrical Engineering and a cum Laude PhD degree in Microsystems Engineering.

Abstract

Organ-on-a-Chip technology as a routine tool in drug discovery and development
Organ-on-a-Chip technology is a new paradigm in drug testing. The technology has as its aim to raise the physiological relevance of traditional cell culture by combining this with microfluidic techniques. Organs-on-a-Chip are 3D tissues that capture the complexity of in vivo tissues including 3D morphology, extracellular matrix embedment, multiple cell types, vascular structure and perfusion flow.

In this presentation I will introduce culture and interrogation of complex 3D tissues, such as liver, kidney, gut and brain tissue. The tissues are grown on the OrganoPlate® platform [1, 2, 3], that allow culturing of over 40 tissues in parallel. The tissues are embedded in an extracellular matrix gel and comprise both stromal tissue, bloodvessel structures as well as epithelial barriers with clear apical and basal sides. The platform can be interrogated using automated imaging equipment as well as all standard equipment including fluorescence-based assays, immunohistochemical staining, barrier integrity monitoring, transport studies, viability assays, qRT-PCR, ELISA’s and many others. Last but not least, operation of the platform is thus straightforward that an end-user who is not necessarily an expert in the field of microfluidics is able to perform the study. In this presentation I will show examples of Organ-on-a-Chip tissues for use in drug safety testing and disease modelling.

[1] S J Trietsch, M C Setyawati, M K Vormann, K J Wilschut, H L Lanz, A Nicholas, C P Ng, D Kurek, J Joore, S Kustermann, A Roth, T Hankemeier, A Moisan, P Vulto, Perfused intestinal tubules for real-time assessment of drug-induced barrier disruption, Nature communications 2017, 8 (1), 262
[2] V. van Duinen, A. van den Heuvel, S.J. Trietsch, H.L. Lanz, J.M van Gils, A.J. van Zonneveld, P. Vulto, T. Hankemeier, 96 perfusable blood vessels to study vascular permeability in vitro, Scientific reports, 2017, 7 (1), 18071
[3] Nienke R. Wevers, Remko van Vught, Karlijn J. Wilschut, Arnaud Nicolas, Chiwan Chiang, Henriette L. Lanz, Sebastiaan J. Trietsch, Jos Joore, Paul Vulto, Drug candidate evaluation on 3D networks of neurons and glia in a microfluidic platform, Scientific Reports 2016, 6, 38856
Marcel Levi
University College London Hospitals

13 February
Jan van de Winkel
Genmab

13 February
Annemarie Jorritsma
NVP

13 February
Ton Rijnders
Lygature & Oncode Institute

13 February
Koen Kas
UGhent & HealthSkouts

13 February
Rajiv Vaid Basaiawmoit
Aarhus University & Biosymfonix

12 & 13 February

Claudia Rijcken
pharmi

13 February

Inge Huitinga
Netherlands Brain Bank

13 February
Wiro Niessen
Erasmus MC, TU Delft & Quantib

13 February
Els Beirnaert
Aelin Therapeutics

13 February
Joep Muijrers
PureTech Health

13 February
Koenraad Wiedhaup
McKinsey & Company

12 & 13 February
Esther Talboom-Kamp
Saltro Diagnostics

13 February
Elise Meijer
Antwerp Management School & Accenture Strategy

13 February
Carine van den Brink
Axon Lawyers

12 February
Tim Knotnerus
AgomAb Therapeutics

13 February
Sjaak Vink
TheSocialMedwork

13 February
Hans Schikan
Topsector Life Sciences & Health

13 February
Thijn Brummelkamp
Scenic Biotech

13 February
Nadine Rouleaux
Maastricht University

13 February
Charlotte Kluit
MSD

13 February
Dharminder Chahal
SkylineDx, Van Herk Investments, Swanbridge

13 February

Marianne van der Steen
RegMedXB & Maastricht University

12 & 13 February

Jan de Kerpel
Kempen & Co

13 February

Wim Van Hecke
icoMetrix

13 February
Wiesje van der Flier 
Alzheimercentrum Amsterdam

13 February
Niels Prins
Brain Research Center & Alzheimercentrum Amsterdam

13 February
Marco Blom
Alzheimer Nederland
Edwin Moses
Achilles Therapeutics & Evox Therapeutics
Carl Moons
Health Innovation Initiative Holland
Jan Kimpen
Philips
Linda van de Burgwal 
Vrije Universiteit Amsterdam
Onno van de Stolpe
Galapagos
Ton van der Steen
Erasmus MC, Medical Delta & STW
Sangbreeta Moitra 
Founder, International Keynote Speaker & Global Strategist
Eline Vrijland-van Beest
NightBalance & Philips
Kim Peters
Healthnovum
Gideon Bevelander
Johnson & Johnson Innovation
Giuseppe Marzio
Chiaro
Wijnand IJsselsteijn
Eindhoven University of Technology
Francesco De Rubertis
Medicxi
André van de Sande
André van de Sande Consultancy BV
Travis McCready
President and CEO, Massachusetts Life Sciences Center
Kees van der Klauw
e/MTIC & NL AI Coalition
Maroeska Rovers
Health Innovation Initiative Holland
Christina Takke 
V-Bio Centures
Focco Vijselaar 
Ministerie van Economische Zaken en Klimaat
Juliette Audet 
Forbion
Felice Verduyn 
LSP

12 February
Thijs Cohen Tervaert 
INKEF

12 February
Tjarda Molenaar
NVP

13 February
Willemijn Vader 
VitroScan B.V.

13 February
Thomas Hankemeier 
Leiden University

13 February
Henk-Jan Guchelaar
Leiden University Medical Center

13 February
Jos Lunenberg
ENPICOM BV

13 February
Peter de With
Eindhoven University of Technology

13 February
Natal van Riel
Eindhoven University of Technology

13 February
Bart van Zijll Langhout
Janssen Strategic Alliances EMEA & Janssen NL Campus Lead

13 February
Jan Peter Balkenende
Former Prime Minister

13 February
Elena Fernandez-Kleinlein
JLABS EMEA

13 February
Robert Vries
Hubrecht Organoid Technology

13 February
Peter Roevens
Janssen Pharmaceutica NV

13 February
Stefan Luzi
Gilde Healthcare

13 February
Peter Haasjes
Nextgenventures

12 February
Brigitte Drees 
Pivot Park

12 February
Femke van de Hoef
Loyens & Loeff

12 February
Dries Fransen van de Putte
Loyens & Loeff

12 February
Rob de Ree
Biogeneration Ventures

13 February
Sponsors & Partners 2020
Host sponsor
Erasmus MC
Host sponsor
Gemeente Rotterdam
Host sponsor
Life Sciences & Health 010
Platinum sponsor
Platinum sponsor
Gold sponsor
Silver sponsor
Silver sponsor
Programme Sponsor AI
Award sponsor
AXON Lawyers
Media sponsor
Powered by
Hyphen Projects
© 2019 Innovation for Health
Hyphen Projects uses cookies to remember certain preferences.